原发性肝细胞癌的常用临床分期  

Clinical staging systems for hepatocellular carcinoma

作　　者：章贵霞 管鸣诚 王明达 李超 姚岚清 朱虹[1] 杨田 Zhang Guixia;Guan Mingcheng;Wang Mingda;Li Chao;Yao Lanqing;Zhu Hong;Yang Tian(Department of Oncology,the First Affiliated Hospital of Soochow University,Suzhou 215006,China;Department of Hepatobiliary Surgery,Eastern Hepatobiliary Surgery Hospital of Naval Medical University,Shanghai 200438,China)

机构地区：[1]苏州大学附属第一医院肿瘤科,215006 [2]海军军医大学东方肝胆外科医院肝脏外科,上海200438

出　　处：《中华实验外科杂志》2021年第12期2549-2551,共3页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金(82171834、81972726、81871949、81572345);江苏省六大人才高峰项目(WSN-102);苏州市第四批姑苏卫生重点人才项目。

摘　　要：原发性肝细胞癌(以下简称肝癌)是恶性程度最高的肿瘤之一。不同阶段的肝癌所采取的治疗方案不同,预后亦不相同。因此,肝癌的临床分期对治疗方案的选择以及长期预后的评估至关重要。截至目前,世界各地已提出了多种肝癌分期系统,如TNM分期、巴塞罗那分期、东方分期、香港肝癌分期和中国肝癌分期等。本文旨在分析常用的肝癌分期,并探讨其在临床实践中的优势和局限性。Hepatocellular carcinoma(HCC)is one of the most malignant tumors.Different stages of HCC have different treatment regimens and different prognosis,so a clinical staging system is crucial for guiding treatment strategies and predicting long-term prognosis.To date,several staging classifications have been launched globally,including Tumor-Node-Metastasis staging,Barcelona Clinic Liver Cancer staging,Eastern staging,Hong Kong Liver Cancer staging,and China Liver Cancer staging.This review aimed to analyze these staging systems for HCC,as well as discussed their advantages and limitations in the current clinical practice.

关 键 词：肝细胞癌 临床分期 预后评估 治疗选择 

分 类 号：R735.7[医药卫生—肿瘤]